Dr. Donna McNamara on PARP Inhibitors for Ovarian Cancer Treatment

Donna McNamara, MD
Published: Tuesday, Jan 20, 2015


Donna McNamara, MD, Co-Chief of the Gynecologic Oncology Division and Medical Oncologist for the Breast Oncology Division at the John Theurer Cancer Center, talks about the benefits of PARP inhibitors for women with BRCA1 or BRCA2-mutated, platinum-sensitive ovarian cancer.

Since the majority of ovarian cancer is diagnosed at later stages, it is estimated that 75% of ovarian cancer patients will recur, McNamara says. 

The SOLO2 trial looked at olaparib, a PARP inhibitor, as maintenance treatment for a women with BRCA-positive ovarian cancer who have recurred after 6 months of treatment. 

For these patentsPARP inhibitors may significantly prolong their disease-free interval by at least 7 months, says McNamara. 


Donna McNamara, MD, Co-Chief of the Gynecologic Oncology Division and Medical Oncologist for the Breast Oncology Division at the John Theurer Cancer Center, talks about the benefits of PARP inhibitors for women with BRCA1 or BRCA2-mutated, platinum-sensitive ovarian cancer.

Since the majority of ovarian cancer is diagnosed at later stages, it is estimated that 75% of ovarian cancer patients will recur, McNamara says. 

The SOLO2 trial looked at olaparib, a PARP inhibitor, as maintenance treatment for a women with BRCA-positive ovarian cancer who have recurred after 6 months of treatment. 

For these patentsPARP inhibitors may significantly prolong their disease-free interval by at least 7 months, says McNamara. 


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x